Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.

Bruno BockornyTeresa MacarullaValerya SemenistyErkut Hasan Borazanci Jaime Feliú-Batlle Mariano Ponz-Sarvisé David Gutierrez Abad Paul E ObersteinAngela AlistarAndres MuñozRavit Geva Carmen Guillén-PonceMercedes Salgado FernandezAmnon PeledMarya F ChaneyIrit Gliko-KabirLiron Shemesh-DarvishDebby IckowiczElla SoraniShaul KadoshAbi Vainstein-HarasManuel Hidalgo

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Triple combination of motixafortide, pembrolizumab, and chemotherapy was safe and well tolerated, and showed signs of efficacy in a population with poor prognosis and aggressive disease.

Keyphrases

poor prognosis
advanced non small cell lung cancer
phase ii
long non coding rna
squamous cell carcinoma
small cell lung cancer
clinical trial
phase iii
study protocol
locally advanced
open label
epidermal growth factor receptor
randomized controlled trial
radiation therapy
chemotherapy induced